CJMB logo

CALLAN JMB INC

CJMBNASDAQ
πŸ† #5059 by market capUS Equity
$0.30β–Ό $0.02 (βˆ’7.10%)
Market closed Β· at close
πŸ””
Track CJMB
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 7.1%
7dβ–Ό 21.8%
14dβ–² 7.5%
30dβ–Ό 46.3%
ytdβ–Ό 72.4%
1yβ–Ό 91.1%
🏦Market Cap
$2M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-13.8%
Declining
πŸ“ŠGross Margin
39.9%
Healthy
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
0.6x
Cheap
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$0.30 – $0.32
52-Week Range
$0.26 – $5.61
Volume (shares)
71,055
Avg Volume (shares)
β€”
Shares Outstanding
5.8M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$6M
Last Q Revenue
$1M
P/E Ratio
β€”
P/S Ratio
0.6x
EPS (TTM)
$-1.97
Dividend Yield
β€”
Dilution (1yr)
βˆ’26.7%
CJMB logo

CALLAN JMB INC

CJMB
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$6Mβ–Ό βˆ’12.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
36.8%β–Ό βˆ’5.8% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$6Mβ–² +185.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$5Mβ–Ό βˆ’1144.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
4.4Mβ–Ό βˆ’26.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$129Kβ–Ό βˆ’$1M YoY
StockOtter Β· stockotter.space

About CALLAN JMB INC

Callan JMB Inc., operating primarily through its subsidiary Coldchain Technology Services, LLC, specializes in providing temperature-controlled logistics solutions specifically for the life sciences sector. The company's services include comprehensive frozen shipping capabilities essential for a wide range of sensitive biological and medical materials. These critical shipments encompass items such as personalized medicines, cell-based therapies, stem cells, cell lines, vaccines, diagnostic samples, reproductive materials (including semen, eggs, and embryos), cord blood, organs, biopharmaceutical products, infectious substances, and other vital commodities. Additionally, Callan JMB Inc. offers packaging services for other perishable (non-pharmaceutical) client goods, alongside technical support. The company was founded in 2006 and is based in Spring Branch, Texas.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

GlobeNewsWireΒ·10d ago

Callan JMB CEO and Management Team Invest $1.5 Million in Common-Only Transaction at a Premium of $1.10 Per Share, Reinforcing Confidence in Growth Strategy

SPRING BRANCH, Texas, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Callan JMB Inc. (NASDAQ: CJMB) (β€œCallan JMB” or the β€œCompany”), a provider of logistics, emergency preparedness, and critical supply chain solutions for the healthc

Globe News WireΒ·20d ago

Callan JMB Announces Arrival of Rapid Dose Therapeutics’ QuickStripβ„’, Resulting in $15 Million in Projected Revenue Over the Next 18 months

Milestone advances Callan JMB's domestic pharmaceutical manufacturing strategy and is expected to create a new high-margin healthcare manufacturing revenue stream at their Texas facility. SPRING BRANCH, Texas, Nov. 02, 2

GlobeNewsWireΒ·Oct 22

Callan JMB to Break Ground on IV Bag Manufacturing Facility Fully Funded by Non-Dilutive and Non-Interest-Bearing Third-Party Partnership

The non-dilutive $16 million capital investment from a third party for Atlas Complex construction advances Callan JMB's pharmaceutical manufacturing strategy and strengthens its role in U.S. healthcare supply-chain prepa

GlobeNewsWireΒ·Oct 20

Callan JMB Advances IV Bag Manufacturing Facility with Projected $450 Million in Annual Revenue

Planned $16 million facility at the Atlas Complex advances Callan JMB's pharmaceutical manufacturing strategy and strengthens its role in U.S. healthcare supply-chain preparedness SPRING BRANCH, Texas, Oct. 20, 2026 (GLO

GlobeNewsWireΒ·Oct 8

Callan JMB Advances U.S. Pharmaceutical Manufacturing at the Atlas Complex and Expands into North American Equipment Distribution and Assembly

Approximately $28 million in planned TRUKING equipment advances domestic manufacturing capacity, strengthens the Company's preparedness strategy, and supports new commercial opportunities

GlobeNewsWireΒ·Aug 27

Callan Power to Acquire Williston Basin Non-Operated Oil and Gas Assets with $48 Million Proved PV-10 and $83 Million 3P PV-10 from The Pfanenstiel Company, Significantly Expanding Energy Assets

Acquisition includes interests across 377 producing wells, approximately 150 BOE/day of current net production, and 27 additional wells in process, with $48 million of proved PV-10 and an illustrative 21% unlevered cash